Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;85(1):32-38.
doi: 10.1111/cod.13776. Epub 2021 Jan 18.

Topical corticosteroid allergy: Results of sequential testing to a corticosteroid series in New Zealand

Victoria L Murphy  1 , Denesh C Patel  1   2 , Steven R Lamb  1   2 , Harriet S Cheng  1   2
Affiliations

Topical corticosteroid allergy: Results of sequential testing to a corticosteroid series in New Zealand

Victoria L Murphy et al. Contact Dermatitis. 2021 Jul.

Abstract

Background: Our institution tests the European Baseline Series (EBS) and a steroid series sequentially in all patients presenting for patch testing. The rate of steroid sensitization in New Zealand has not previously been documented.

Objectives: To investigate the rate of corticosteroid sensitization and assess additional benefit of testing the full steroid series over the steroid allergy markers in the EBS.

Methods/patients: Retrospective analysis of all patient demographics and patch test results over a 5-year period (2014 to 2019) was performed at a tertiary patch test clinic in Auckland, New Zealand.

Results: A total of 319 patients completed patch testing, and 4.4% were sensitized to one or more corticosteroids. As much as 79% of positive reactions were of current relevance; 11/14 reactions were to tixocortol pivalate or budesonide. The "number needed to test" to detect one additional case of corticosteroid sensitization by using the full corticosteroid series over the EBS alone was 107.

Conclusions: Although corticosteroid sensitization was not uncommon in our population, the results suggest that sequential testing with the corticosteroid markers (budesonide and tixocortol) in the standard series alone is adequate. The additional corticosteroid series should be added if the markers are positive or where there is a clinical suspicion of corticosteroid allergy.

Keywords: allergic contact dermatitis; atopic dermatitis; cross-reactions; irritant contact dermatitis; occupational; patch test; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. quiz 16-18.
    1. Pharmaceutical data web tool version August 3, 2020 (data extracted from Pharmaceutical Collection on March 5, 2020). Ministry of Health. 2020. https://minhealthnz.shinyapps.io/pharmaceutical_data_web_tool/. Accessed August 10, 2020.
    1. Sapsford S, Judd L, Cheng HS. Patch testing in New Zealand: barriers to evidence-based care. Australas J Dermatol. 2019;60(4):E371-E372.
    1. Baeck M, Chemelle JA, Goossens A, Nicolas JF, Terreux R. Corticosteroid cross reactivity: clinical and molecular modelling tools. Allergy. 2001;66(10):1367-1374.
    1. Burden AD, Beck MH. Contact hypersensitivity to topical corticosteroids. Br J Dermatol. 1992;127(5):497-500.

Substances

Grants and funding

LinkOut - more resources